FDA Speeds up Approval for Ovarian Cancer Drugs
The news headline “FDA Regulator, Widowed by Cancer, Helps Speed Drug Approval” has created quite a sensation globally.
NICE’s Ovarian Cancer Guideline Rejects Three Drugs, but Recommends Two.
The National Institute for Health and Care excellence have drafted guidelines for the treatment of recurrent ovarian cancer, which recommend two therapies for NHS use but have also rejected a further three drugs.